Allen Ferrucci, MD
Foot and Ankle Surgery · Hamden, CTNPI 1578721072
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), royalties or licence payments and food and beverage — rather than concentrated in one kind of arrangement. Gramercy Extremity Orthopedics LLC accounts for 81.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $4,236 and has fallen 59.3% since, to $1,725 in 2025.
Across 175 payments — averaging $71.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gramercy Extremity Orthopedics LLC$10K
- Amgen$907
- Stryker$387
- Johnson & Johnson$346
- Smith+Nephew$245
- Paragon 28, Inc.$74
- plus $413 from 15 others
Across 7 payments — averaging $35,714 each. An ownership or investment interest held by the physician or an immediate family member.
- Gramercy Extremity Orthopedics LLC$250K
What the payments were for
- Royalty or licence$3,62029%
- Consulting fees$6,25050%
- Food & beverage$2,63921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gramercy Extremity Orthopedics LLC | 34 | $10,137 |
| Amgen | 87 | $907 |
| Stryker | 10 | $387 |
| Johnson & Johnson | 16 | $346 |
| Smith+Nephew | 5 | $245 |
| Paragon 28, Inc. | 1 | $74 |
| Endo USA, Inc. | 4 | $74 |
| Zimmer Biomet | 1 | $45 |
| Pacira Therapeutics, Inc. | 2 | $42 |
| Bioventus LLC | 2 | $40 |
| Orthofix Medical, Inc. | 3 | $31 |
| Celularity Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Treace Medical Concepts, Inc. | 1 | $19 |
| Dynasplint Systems Inc. | 1 | $19 |
| Innovation Technologies Inc | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Zimvie Inc. | 1 | $13 |
| Globus Medical | 1 | $10 |
How this compares
$12,509 in reported general payments places this provider in the 85th percentile of 89 foot and ankle surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 31 | $4,286 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $393 |
| Celecoxib | 42 | $304 |
| Cephalexin | 22 | $243 |
| Methylprednisolone | 13 | $77 |
| Cyclobenzaprine Hcl | 19 | $61 |
| Tramadol Hcl | 14 | $32 |
| Meloxicam | 17 | $28 |
Paid to pharmacies, not to this prescriber.
Other foot and ankle surgery in Hamden
- David CaminearHamden$47K
- Nicola CorbettHamden$6K
- Jeffrey DelottHamden$4K
- Zubaria SaroojHamden$2K
- Thomas McDonaldEnfield$241K
- Jossie AbrahamNorwalk$152K
- Gabriel GambardellaBloomfield$99K
- James DejesusNaugatuck$40K
- William ProbascoFairfield$26K
- Adebola AdelekeMiddletown$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.